Profile editing will be unavailable for Scholars@Duke profiles from June 11-24, 2026 as manual profile data entry transitions to Elements.
More information about the transition.
cancel
Zhiguo Li
Associate Professor of Biostatistics & Bioinformatics
Journal ArticleStat Med · May 2026
When the proportional hazards assumption does not hold, the hazard ratio can misrepresent treatment effects in survival analysis. We evaluate the win ratio, originally proposed for prioritizing multiple outcomes, as an effect size measure for a single surv ...
Full textLink to itemCite
Journal ArticleLifetime Data Anal · April 2, 2026
Two-stage randomized trials, or the more general sequential multiple assignment randomized trials (SMART), have been increasingly used in studying adaptive treatment strategies for treating chronic diseases or conditions where treatments need to be adjuste ...
Full textLink to itemCite
Journal ArticleStat Med · February 2026
In a weighted logrank test, such as the Harrington-Fleming test and the Tarone-Ware test, predetermined weights are used to emphasize early, middle, or late differences in survival distributions to maximize the test's power. The optimal weight function und ...
Full textLink to itemCite
ConferenceBlood · November 3, 2025
AbstractIntroduction: Isocitrate dehydrogenase (IDH) mutations are observed in ~20% of patients with acute myeloid leukemia (AML). In the U ...
Full textCite
ConferenceBlood · November 3, 2025
AbstractBackground and Significance: Current therapies for steroid-refractory chronic graft versus host disease (SR-cGVHD) feature limited ...
Full textCite
Journal ArticleLifetime Data Anal · October 2025
Data analysis methods have been well developed for analyzing data to make inferences about adaptive treatment strategies in sequential multiple assignment randomized trials (SMART), when data are continuous or right-censored. However, in some clinical stud ...
Full textLink to itemCite
Journal ArticleJ Oncol Pharm Pract · April 2024
BACKGROUND: Invasive fungal infection (IFI) prophylaxis is recommended in patients with acute myeloid leukemia (AML) during induction chemotherapy. Posaconazole (POSA) is the recommended agent of choice; however, this medication can be associated with QTc ...
Full textLink to itemCite
Journal ArticleJ Oncol Pharm Pract · April 2024
INTRODUCTION: It has long been established that high-dose methotrexate is an essential part of therapy for primary central nervous system lymphoma. When regimens utilizing high-dose methotrexate were first studied, a dose of 8 g/m2 was used. More recently, ...
Full textLink to itemCite
Journal ArticleBlood advances · February 2024
AbstractChronic graft-versus-host disease (cGVHD) is a debilitating, autoimmune-like syndrome that can occur after allogeneic hematopoietic stem cell transplantation. Constitutively activated B cells contribute to ongoing alloreactivity and autore ...
Full textOpen AccessCite
Journal ArticleProc Natl Acad Sci U S A · December 12, 2023
Thrombocytopenia, hemorrhage, anemia, and infection are life-threatening issues following accidental or intentional radiation exposure. Since few therapeutics are available, safe and efficacious small molecules to mitigate radiation-induced injury need to ...
Full textLink to itemCite
Journal ArticleCancer Res Commun · December 5, 2023
UNLABELLED: Approximately half of patients with cancer receive radiotherapy and, as cancer survivorship increases, the low rate of radiation-associated sarcomas is rising. Pharmacologic inhibition of p53 has been proposed as an approach to ameliorate acute ...
Full textLink to itemCite
Journal ArticleTransplant Cell Ther · March 2023
Despite the exciting advancement of novel therapies, chronic graft-versus-host disease (cGVHD) remains the most common cause of non-relapse mortality after allogeneic hematopoietic stem cell transplantation (HCT). Frontline treatment of cGVHD involves syst ...
Full textLink to itemCite
Journal ArticleAnn Hematol · February 2023
Multiple myeloma (MM) remains an incurable disease and there is an unmet medical need for novel therapeutic drugs that do not share similar mechanisms of action with currently available agents. Sphingosine kinase 2 (SK2) is an innovative molecular target f ...
Full textLink to itemCite
Journal ArticleCancer Lett · October 1, 2022
Many patients with multiple myeloma (MM) have comorbidities and are treated with PPAR agonists. Immunomodulatory agents (IMiDs) are the cornerstones for MM therapy. Currently, little is known about how co-administration of PPAR agonists impacts lenalidomid ...
Full textLink to itemCite
Journal ArticleRadiat Res · February 1, 2022
Radiation can be applied for therapeutic benefit against cancer or may result in devastating harm due to accidental or intentional release of nuclear energy. In all cases, radiation exposure causes molecular and cellular damage, resulting in the production ...
Full textLink to itemCite
Journal ArticleJournal of Systems Science and Complexity · February 1, 2022
Option pricing problem is one of the central issue in the theory of modern finance. Uncertain currency model has been put forward under the foundation of uncertainty theory as a tool to portray the foreign exchange rate in uncertain finance market. This pa ...
Full textCite
Journal ArticleFront Immunol · 2022
Alloreactive donor T cells undergo extensive metabolic reprogramming to become activated and induce graft-versus-host disease (GVHD) upon alloantigen encounter. It is generally thought that glycolysis, which promotes T cell growth and clonal expansion, is ...
Full textLink to itemCite
Journal ArticleFront Immunol · 2022
De novo immune responses to myeloid and other blood-borne tumors are notably limited and ineffective, making our ability to promote immune responses with vaccines a major challenge. While focus has been largely on cytotoxic cell-mediated tumor eradication, ...
Full textOpen AccessLink to itemCite
ConferenceBlood · November 5, 2021
AbstractBackground: Relapsed Acute Lymphoblastic Leukemia (ALL) is not curable with standard therapies. Effective outpatient treatment, allowing patients to maintain a good quality of life, while offering a ...
Full textCite
Journal ArticleCancer Invest · November 2021
Novel therapeutics are needed for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Everolimus is an mTOR pathway inhibitor with synergistic anti-tumor activity when combined with histone deacetylase inhibitors, such as panobi ...
Full textLink to itemCite
Journal ArticleBlood · May 6, 2021
Patients with chronic graft-versus-host disease (cGVHD) have increased B cell-activating factor (BAFF) levels, but whether BAFF promotes disease after allogeneic bone marrow transplantation (allo-BMT) remains unknown. In a major histocompatibility complex- ...
Full textLink to itemCite
Journal ArticleBone Marrow Transplant · January 2021
Prophylactic donor lymphocyte infusions (DLI) are used to augment post-transplant immune recovery to reduce both infectious complications and disease recurrence. Preclinical studies implicate the naive T-cell subset as the primary driver of graft-versus-ho ...
Full textLink to itemCite
ConferenceBlood · November 5, 2020
Allogeneic hematopoietic cell transplant (HCT) improves survival in patients with relapsed or high risk acute myeloid leukemia (AML). Complete remission (CR) is typically a pre-requisite for transplantation, though many do not achieve a formal CR. ...
Full textCite
Journal ArticleJCO Oncol Pract · August 2020
PURPOSE: We performed a retrospective chart review on 393 patients with multiple myeloma (MM) to determine the utility of the gamma gap (GG). METHODS: We calculated the difference between a patient's total serum protein and albumin as a point-of-care test ...
Full textLink to itemCite
Journal ArticleCancer Med · August 2020
We determined the impact of bone marrow fibrosis (BMF) on the clinical outcomes of newly diagnosed multiple myeloma (NDMM) patients in the current era of myeloma therapy. A total of 393 MM patients were included in the final analysis. The median followup w ...
Full textLink to itemCite
Journal ArticleRadiat Res · August 1, 2020
Thrombocytopenia (TCP) may cause severe and life-threatening bleeding. While this may be prevented by platelet transfusions, transfusions are associated with potential complications, do not always work (platelet refractory) and are not always available. Th ...
Full textLink to itemCite
Journal ArticleAm J Hematol · June 2020
Older AML patients have low remission rates and poor survival outcomes with standard chemotherapy. Microtransplantation (MST) refers to infusion of allogeneic hematopoietic stem cells without substantial engraftment. MST has been shown to improve clinical ...
Full textLink to itemCite
ConferenceBlood · November 13, 2019
Our group previously showed that B cells signal aberrantly through the B cell receptor (BCR) in allogeneic hematopoietic stem cell transplant (HCT) patients with active chronic graft-versus-host disease (cGVHD). Preclinical mouse studies have demon ...
Full textCite
ConferenceBlood · November 13, 2019
Introduction/Background:Standard therapy for both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) is myelosuppressive, and patients are expected to be neutropenic for a prolonged period. Due to t ...
Full textCite
Journal ArticleBMC Bioinformatics · May 28, 2019
BACKGROUND: Time- and dose-to-event phenotypes used in basic science and translational studies are commonly measured imprecisely or incompletely due to limitations of the experimental design or data collection schema. For example, drug-induced toxicities a ...
Full textLink to itemCite
Journal ArticleIEEE Access · January 1, 2019
In the foundation of uncertainty theory, uncertain stock model has been put forward to portray the price fluctuation of stocks in a market with uncertain information. In this paper, the model is depicted by uncertain differential equations involved by a Li ...
Full textCite
Journal ArticleStat Med · November 30, 2018
Grouped survival data arise often in studies where the disease status is assessed at regular visits to clinic. The time to the event of interest can only be determined to be between two adjacent visits or is right censored at one visit. In data analysis, r ...
Full textOpen AccessLink to itemCite
Journal ArticleClin Lymphoma Myeloma Leuk · October 2018
BACKGROUND: For patients with aggressive lymphomas who relapse after initial therapy, a durable response is rarely achieved with standard salvage therapies. Significant efforts have focused on the development of novel treatments with reduced toxicity. We c ...
Full textLink to itemCite
Journal ArticleBiol Blood Marrow Transplant · April 2018
Gastrointestinal (GI) complications including graft-versus-host disease (GVHD) are a major cause of morbidity and mortality in allogenic stem transplant recipients. Although several studies have previously looked into the acute GI complications, fewer smal ...
Full textLink to itemCite
Journal ArticleBone Marrow Transplant · January 2018
Single-agent high-dose melphalan (HDM, 200 mg/m2) has been the most commonly used conditioning regimen prior to autologous stem cell transplant, since its introduction in 1992. We used a more aggressive alkylator-based conditioning regimen in an attempt to ...
Full textLink to itemCite
Journal ArticleAm Stat · 2018
The score statistic continues to be a fundamental tool for statistical inference. In the analysis of data from high-throughput genomic assays, inference on the basis of the score usually enjoys greater stability, considerably higher computational efficienc ...
Full textLink to itemCite
ConferenceCommunications in Computer and Information Science · January 1, 2018
Nowadays, healthcare systems have become increasingly patient-centered and the unstructured, open-ended and patient-driven feedback has drawn a significant attention from medical and healthcare organizations. Based on this, we are motivated to harness vari ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2017
8008 Background: The combination of bendamustine, pomalidomide, and dexamethasone (BPd) displays promising activity in heavily pretreated RRMM. In the Phase I portion, MTD was 120 mg/m2bendamustine/3mg pomali ...
Full textCite
Journal ArticleJ Geriatr Oncol · May 2017
OBJECTIVES: Multiple myeloma (MM) primarily strikes older adults, but full-dose chemotherapy such as bortezomib (Velcade), cyclophosphamide and dexamethasone (VCD) is often excessively toxic to very old or frail adults and those with substantial comorbidit ...
Full textLink to itemCite
Journal ArticleStat Med · February 10, 2017
In sequential multiple assignment randomized trials, longitudinal outcomes may be the most important outcomes of interest because this type of trials is usually conducted in areas of chronic diseases or conditions. We propose to use a weighted generalized ...
Full textLink to itemCite
Journal ArticleBiol Blood Marrow Transplant · February 2017
Comprehensive recommendations for maintenance therapy after autologous stem cell transplantation (ASCT) for patients with multiple myeloma (MM) have yet to be defined. Bortezomib has been utilized as maintenance therapy after ASCT, but data attesting to th ...
Full textLink to itemCite
ConferenceBlood · December 2, 2016
AbstractIncreased B cell-activating factor (BAFF) and aberrant B cell survival and activation are associated with chronic graft versus host disease (cGVHD) in patients. Whether excessive BAFF production has ...
Full textCite
ConferenceBlood · December 2, 2016
AbstractAllogeneic hematopoietic stem cell transplantation (HCT)-related immune pathology severely limits patient (Pt) survival, largely due to infections. Chronic graft versus host disease (cGVHD) Pts are p ...
Full textCite
Journal ArticleJ Hematol Oncol · August 17, 2016
BACKGROUND: The binding of CXCR4 with its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoietic stem cell transplantation (HSC ...
Full textOpen AccessLink to itemCite
Journal ArticleScand Stat Theory Appl · June 2016
In some applications, the failure time of interest is the time from an originating event to a failure event, while both event times are interval censored. We propose fitting Cox proportional hazards models to this type of data using a spline-based sieve ma ...
Full textLink to itemCite
Journal ArticleNucleic Acids Res · May 19, 2016
In cultured cancer cells the E3 ubiquitin ligase Rad18 activates Trans-Lesion Synthesis (TLS) and the Fanconi Anemia (FA) pathway. However, physiological roles of Rad18 in DNA damage tolerance and carcinogenesis are unknown and were investigated here. Prim ...
Full textOpen AccessLink to itemCite
Journal ArticleSci Rep · July 22, 2015
Chronic hepatitis B virus (HBV) infection is a major global health burden. Functional exhaustion and numerical reduction of HBV-specific cytotoxic T lymphocytes (CTLs) in the liver and peripheral blood limit anti-HBV CTL activity in patients with chronic H ...
Full textLink to itemCite
Journal ArticleJ Clin Apher · June 2015
High-dose cyclophosphamide (Cy) is frequently employed for peripheral blood mobilization of hematopoietic stem cells before high-dose chemotherapy with autologous stem cell transplantation (ASCT) in multiple myeloma (MM). The benefit of mobilization with C ...
Full textLink to itemCite
Journal ArticleStat Med · February 28, 2014
In studying adaptive treatment strategies, a natural question that is of paramount interest is whether there is any significant difference among all possible treatment strategies. When the outcome variable of interest is time-to-event, we propose an invers ...
Full textLink to itemCite
Journal ArticleBiol Blood Marrow Transplant · February 2014
We present a comparative study on 124 patients with hematologic malignancies who had undergone reduced-intensity conditioning and then received a transplant from an HLA-matched related (MRD), an HLA-matched unrelated (MUD), or an HLA-haploidentical related ...
Full textLink to itemCite
Journal ArticleBlood · November 7, 2013
Acute graft-versus-host disease (aGVHD) is the leading cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Approximately 35% to 50% of HCT recipients develop aGVHD; however, there are no validated diagnostic and pred ...
Full textLink to itemCite
Journal ArticleTransplantation · April 27, 2013
BACKGROUND: Little is known about the immunologic events surrounding pancreatic ischemia-reperfusion injury (IRI) because of a lack of established experimental models. The purpose of this study was to develop a mouse model for pancreatic IRI to serve as a ...
Full textLink to itemCite
Journal ArticleInt J Radiat Oncol Biol Phys · March 15, 2013
PURPOSE: To investigate whether and how insulin-like growth factor 1 (IGF-1) mitigates hematopoietic toxicity after total body irradiation. METHODS AND MATERIALS: BALB/c mice were irradiated with a lethal dose of radiation (7.5 Gy) and treated with IGF-1 a ...
Full textLink to itemCite
Journal ArticleLeuk Res · January 2013
PURPOSE: The decision to re-induce patients with acute myeloid leukemia (AML) based on results of the day 14 bone marrow (BM) biopsy is variable and lacks evidence based data. The aim of our review was to evaluate the accuracy of a day 14 BM biopsy in dete ...
Full textLink to itemCite
Journal ArticleBlood · October 4, 2012
Graft-versus-host disease (GVHD) remains the most common cause of nonrelapse-related morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although T-cell depletion and intensive immunosuppression are effective in th ...
Full textLink to itemCite
Journal ArticleGenet Epidemiol · September 2012
For many clinical studies in cancer, germline DNA is prospectively collected for the purpose of discovering or validating single-nucleotide polymorphisms (SNPs) associated with clinical outcomes. The primary clinical endpoint for many of these studies are ...
Full textLink to itemCite
Journal ArticleBone Marrow Transplant · May 2012
Primary graft failure after allogeneic hematopoietic cell transplantation is a life-threatening complication. A shortened conditioning regimen may reduce the risk of infection and increase the chance of survival. Here, we report the outcome of 11 patients ...
Full textLink to itemCite
Journal ArticleLeuk Lymphoma · February 2012
Patients with chronic lymphocytic leukemia (CLL) with deletion or mutation of TP53 have exceedingly poor clinical outcomes. Cenersen, an oligonucleotide targeting TP53, has been shown to abrogate the activity of TP53 gain-of-function mutants and to increas ...
Full textLink to itemCite
Journal ArticleClin Ther · December 2011
BACKGROUND: Initiation of antidepressant treatment for depression may be associated with new onset (emergent) anxiety. OBJECTIVE: The purpose of this study was to assess demographic and clinical factors associated with emergent anxiety following a new anti ...
Full textLink to itemCite
Journal ArticleCanadian Journal of Statistics · December 1, 2011
We propose using the weighted likelihood method to fit a general relative risk regression model for the current status data with missing data as arise, for example, in case-cohort studies. The missingness probability is either known or can be reasonably es ...
Full textCite
Journal ArticleBiometrika · September 2011
Two-stage randomized trials are growing in importance in developing adaptive treatment strategies, i.e. treatment policies or dynamic treatment regimes. Usually, the first stage involves randomization to one of the several initial treatments. The second st ...
Full textLink to itemCite
Journal ArticleInt J Radiat Biol · August 2011
PURPOSE: To present previously unavailable data on the use of stem cell administration to aid recovery of victims of the Chernobyl disaster. On 26 April 1986, an accident at Unit 4 of the Chernobyl Nuclear Power Plant took place during the planned test of ...
Full textLink to itemCite
Journal ArticleCancer Invest · January 2011
INTRODUCTION: High relapse rates and infections remain primary causes of failure in nonmyeloablative transplantation. Interleukin-2 (IL-2) may stimulate the immune system and improve outcomes. The primary objective of this pilot study was to evaluate the f ...
Full textLink to itemCite
Journal ArticleAmerican Statistician · November 1, 2010
In biomedical studies and other areas, there are often situations where parameters are known to be ordered. In these situations, incorporating the order restriction can produce much more efficient estimates than ignoring it. There is much research on point ...
Full textCite
Journal ArticleBiometrics · December 2008
Grouped failure time data arise often in HIV studies. In a recent preventive HIV vaccine efficacy trial, immune responses generated by the vaccine were measured from a case-cohort sample of vaccine recipients, who were subsequently evaluated for the study ...
Full textLink to itemCite
Journal ArticleStat Med · August 15, 2007
We consider the situation of two ordered categorical variables and a binary outcome variable, where one or both of the categorical variables may have missing values. The goal is to estimate the probability of response of the outcome variable for each cell ...
Full textLink to itemCite
Journal ArticleClin Trials · 2006
BACKGROUND: Phase II clinical trials in cancer are used to assess whether a new agent has sufficiently promising efficacy to proceed on to a larger definitive study comparing the new agent to a standard agent. PURPOSE: A crucial issue in determining the us ...
Full textLink to itemCite